Anika Therapeutics ANIK Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$11.36M+80.0% | -$11.17M+80.2% | -$33.04M+66.1% | -$60.63M+18.3% | -$56.74M+26.1% | ||
| $5.4M-17.4% | $5.37M-22.0% | $5.61M-19.2% | $6.08M-9.0% | $6.53M-0.5% | ||
| $13.86M+11.8% | $10.08M-23.2% | $9.88M-32.7% | $11.06M-25.6% | $12.4M-17.9% | ||
| $83K— | -$7K— | $252K— | —— | —— | ||
| —— | —— | -$1.81M-1,018% | -$2.36M— | -$2.56M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $740K+126% | $42K+102% | -$956K— | -$4.12M— | -$2.86M— | ||
| —— | —— | —— | —— | —— | ||
| -$802K— | -$2.33M— | -$1.07M— | —— | —— | ||
| —— | —— | -$372K-138% | $888K— | $562K— | ||
| $1.95M-9.9% | $2.06M-4.1% | $2.15M-0.4% | $2.24M+5.8% | $2.16M-4.1% | ||
| $6.47M+19.9% | $11.19M+107% | $8.13M— | $6.28M— | $5.4M— | ||
| $5.43M-37.9% | $6.83M-11.7% | $7.49M-9.5% | $6.81M-12.6% | $8.75M+49.7% | ||
| —— | —— | —— | —— | $4.5M— | ||
| —— | —— | —— | —— | -$4.85M+17.0% | ||
| —— | —— | —— | —— | $14.89M+297% | ||
| $1.76M-0.8% | $1.57M-39.7% | $1.64M-35.1% | $1.65M-36.9% | $1.77M-37.6% | ||
| -$15.64M+1.6% | -$10.73M+15.7% | -$10.81M-46.5% | -$14.78M-323% | -$15.89M-117% | ||
| —— | —— | —— | $660K— | $91K— | ||
| —— | —— | -$4.38M— | -$9.66M— | -$15.26M— | ||
| —— | $1.08M-73.1% | $1.81M-52.2% | $2.53M-28.7% | $3.26M-2.2% | ||
| —— | —— | —— | —— | —— | ||
| -$802K— | -$2.33M— | -$1.07M— | —— | —— | ||
| $6.02M-86.2% | $5.82M-87.0% | $23.6M-12.0% | $45.81M+849% | $43.48M+811% | ||
| $1.95M-9.9% | $2.06M-4.1% | $2.15M-0.4% | $2.24M+5.8% | $2.16M-4.1% | ||
| $1.52M— | $1.33M— | $483K— | $328K— | —— | ||
| —— | —— | —— | —— | $4.5M— | ||
| $148K-86.8% | $357K-71.1% | $609K-79.2% | $925K-79.7% | $1.12M-81.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $660K— | $91K— | ||
| -$1.9M+10.0% | -$2M+4.1% | -$2.1M-1.1% | -$2.19M-7.4% | -$2.11M+3.1% | ||
| $851K+280% | $896K— | $424K— | $345K— | $224K— | ||
| —— | $0-100% | $1.48M-66.7% | $2.97M0.0% | $4.45M+200% | ||
| $587K-21.3% | $265K-77.6% | $371K-67.4% | $1.22M— | $746K— | ||
| —— | $1.08M-73.1% | $1.81M-52.2% | $2.53M-28.7% | $3.26M-2.2% | ||
| $1.04M— | $4.36M— | —— | —— | —— | ||
| $1.04M— | $4.36M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Anika Therapeutics generate?
- Anika Therapeutics (ANIK) generated $6.5M in operating cash flow over the trailing twelve months.
- What is Anika Therapeutics's free cash flow?
- After $5.4M of capital expenditures, Anika Therapeutics's free cash flow was $1.0M over the trailing twelve months, up 105.4% year over year.
- Where does Anika Therapeutics's cash flow data come from?
- Every line is extracted from Anika Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
